Latest News

Love your Lungs

 Love your Lungs Campaign

On Monday the 13th of February a group of Irish charities have teamed up with Olympic Champion Dr Ronnie Delany to promote healthy lungs by highlighting symptoms of lung disease and the importance of early intervention.  The Irish Lung Health Alliance includes:

  • Irish Thoracic Society
  • Cystic Fibrosis Association of Ireland
  • Irish Lung Fibrosis Association
  • Ben Bulben COPD Support Group
  • Irish Sleep Apnoea Trust
  • Asthma Society of Ireland
  • the Irish Cancer Society
  • Irish Sarcoidosis Network

 

The Love your Lungs campaign carries four simple messages:
1. Lung disease can affect anyone regardless of age, health status and walk of life
2. Symptoms such as persistent cough and shortness of breath are not normal and should be checked with your GP
3. Lung disease is treatable – the earlier you treat the better.
4. Keep lungs healthy - don’t smoke and stay active


The ‘Love Your Lungs’ campaign will see the charities working with medical centres throughout the country to offer free lung function tests for World Spirometry Day taking place in June this year.  It also incorporates a new website, www.lunghealth.ie, offering helpful information and advice regarding common lung conditions as well as patient support and tips on how to keep your lungs healthy.  The website will be updated regularly with details on participating centres over the coming months.

One in five deaths in Ireland is caused by lung disease.  It is the most common reason to visit a GP and the third most common reason for acute hospital admission.  Yet early diagnosis of lung disease, which can vastly improve outcomes and quality of life for patients, continues to be a challenge due to poor awareness levels.  The fact is, shortness of breath, cough and wheeze are not normal and if present should be checked out by your GP,’ said Dr Edward McKone, Consultant Respiratory Physician and President of the Irish Thoracic Society.


‘The campaign also aims to highlight the fact that lung disease affects people of all ages, all socio-economic backgrounds and many non-smokers as well as smokers.  ‘The range of conditions represented by The Lung Health Alliance charities is evidence of the broad-reaching nature of lung disease as they affect everyone from infants to senior citizens.  In fact lung disease is the most prevalent condition reported in young adults (18-24 years of age),’ said Dr McKone.

Olympic legend Dr Ronnie Delany is an ambassador for the campaign underlining the importance of healthy lungs to an active lifestyle and visa versa.  As an Olympic Gold Medallist and the winner of an unprecedented and unsurpassed 40 straight victories “indoors” in America from 1956 to 1959 including 33 mile races,  Dr Delany embodies the link between good lung function and athleticism.


 “We know only too well how dependent athletes are on good lung function. What’s probably less well known is the reverse – the role that sport and physical activity can play in preventing lung disease and in improving quality of life for people with lung conditions. It’s therefore very fitting that the Irish Lung Health Alliance and the World Spirometry Day Campaign have chosen this Olympics year to launch their campaign, said Dr Delany”

 

 

Medical & Research Programmes



Welcome to our Medical & Research Programs Section. Here you will find details of all our latest Programs.

MRCG/HRB Joint Funding Scheme
Monday, 13 December 2010 10:23

The Alpha One Foundation invites research proposals applications for consideration in the Medical Research Charities Group (MRCG) and Health Research Board (HRB) joint funding scheme 2011. This joint funding scheme has been in operation since 2006 and provides funding of up to €100,000 per annum for clearly defined research projects for up to 36 months. Smaller projects are also considered.

For further information about applying for the joint funding scheme please contact Kitty O'Connor by email This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by phone on 01-8093871.

Deadlines for submissions of applications is 5pm Friday the 21st of January 2011.

 
International Collaborative Study To Establish The 1St International (Who) Standard For Alpha-1-Antitrypsin
Monday, 24 November 2008 12:54

Craig Thelwell1, Peter Rigsby2 and Colin Longstaff1

1Biotherapeutics Group, Haemostasis Section and

2Biostatistics Division, National Institute for Biological Standards and Control, South Mimms, Herts EN6

3QG, UK

Read more...
 
Prevalence of Alpha-1 Anitrypsin Deficiency in Ireland
Monday, 24 November 2008 12:52

Author - T. CARROLL, O. FLOYD, C. O’CONNOR, J. McPARTLIN, C. TAGGART, R. COSTELLO, S. J. O’NEILL and N. G. McELVANEY

Institution – Department of Respiratory Research, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland. 

Rationale: AAT deficiency is a hereditary autosomal codominant disorder, resulting from mutations in the AAT gene, and classically presents with emphysema and liver disease.  The most common phenotype presenting with clinical evidence of AAT deficiency is the Z phenotype, resulting in decreased levels of circulating AAT due to retention of the aberrantly folded protein in the liver.  It is unclear whether the carrier status confers increased risk for disease.  Demographic studies indicate that AAT deficiency is under-diagnosed and prolonged delays in diagnosis are common.  World Health Organisation guidelines advocate targeted detection programmes of patients with COPD and asthma. 

Read more...
 
American Thoracic Society Annual Conference 2008
Monday, 24 November 2008 12:50

Conference Abstracts:

American Thoracic Society annual conference 2008.

Title – Evidence for the Activation of the Unfolded Protein Response (UPR) in Monocytes from Alpha-1 Antitrypsin Deficient Individuals

Read more...
 
Immune Cell Function in Alpha-1 Antitrypsin Deficiency
Monday, 24 November 2008 12:49

Immune Cell Function in Alpha-1 Antitrypsin Deficiency

Awarding Body: Talecris Biotherapeutics

Read more...
 
<< Start < Prev 1 2 3 Next > End >>

Page 1 of 3

What is Alpha-1 Antitrypsin?

Alpha-1 Antitrypsin is an important protein produced by the liver, which is released into the bloodstream and travels to the lungs.  Once inside the lungs it provides protection from the destructive effects of infections and harmful irritants, particularly tobacco smoke.

Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, along with cystic fibrosis, is the commonest genetic lung disease in Ireland. It severely affects more than 2,000 people nationally, with another 10,000 individuals also at risk of lung and liver disease. It is the only proven genetic risk factor for COPD.